It is approved by the European Medicines Agency and the United States Food and Drug Administration for the treatment of Still’s disease, gouty arthritis/gout flares, cryopyrin-associated periodic syndromes (CAPS), FMF, TRAPS, and MKD/HIDS [18, 19]. Here, NLRP3 is linked to gout.